Day 3

TIME: Use and duration of bone marrow derived stem cells infusion for the treatment of post infarction ventricular dysfunction.

solaci
solaci
396
0

This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection fraction (LVEF) <45%. An intracoronary infusion with fixed doses of bone marrow derived stem cells vs. placebo was administered (randomization 2:1) 3 days after infarction vs. 7 (randomization 1:1). The objective was to assess ventricular and contractile function of infarct and border zone with MRI at 6 months. LVEF showed no improvement in the stem cell group vs. placebo (p=0,96). Neither were there differences between those treated at 3 vs. 7 days.

Conclusion: A bone marrow derived stem cells infusion did not improve ventricular function after infarction.

Comment: Even though this trial on stem cells enrolled more patients than any other, it failed to show benefits in soft end points such as LVFF using MRI. Clinical end points in these kinds of studies remain elusive

Read article

Read editorial

4_jay_traverse
Jay Traverse
2012-11-06

Original title: The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarction: The NHLBI and CCTRN TIME Trial

Previous article
POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.
Next article
SWISS AMI: Stem cells infusion after primary angioplasty
solaci
solaci

More articles by this author

PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.

solaci - 0
Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion, reduces free radicals and mitochondrial damage. It...

SWISS AMI: Stem cells infusion after primary angioplasty

solaci - 0
The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF ≤45% randomized to placebo, to receive early (before 7 days) or...

POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.

solaci - 0
Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial randomized 30 patients with LV dysfunction due...

SCIPIO trial: Intracoronary infusion of autologous cardiac stem cells improve ventricular function.

solaci - 0
This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy. It consecutively enrolled 37 patients with reduced...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 3

PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.

Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion, reduces free radicals...
solaci -
SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

Dr. Omar Tupayachi - 0
The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

Dr. Omar Tupayachi - 0
As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

Dr. Omar Tupayachi - 0
In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...